Kezar Life Sciences Inc (KZR) Receives $26.50 Consensus Price Target from Analysts
Kezar Life Sciences Inc (NASDAQ:KZR) has received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $26.50.
A number of equities analysts recently weighed in on KZR shares. Zacks Investment Research upgraded Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Saturday, March 16th. William Blair reiterated an “outperform” rating on shares of Kezar Life Sciences in a research report on Tuesday, March 12th.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. boosted its position in Kezar Life Sciences by 2,314.5% during the 3rd quarter. BlackRock Inc. now owns 241,446 shares of the company’s stock worth $5,169,000 after acquiring an additional 231,446 shares during the period. BB Biotech AG acquired a new stake in Kezar Life Sciences during the 4th quarter worth about $19,315,000. Geode Capital Management LLC boosted its position in Kezar Life Sciences by 126.7% during the 4th quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after acquiring an additional 32,441 shares during the period. Bank of New York Mellon Corp acquired a new stake in Kezar Life Sciences during the 4th quarter worth about $411,000. Finally, Slow Capital Inc. acquired a new stake in Kezar Life Sciences during the 4th quarter worth about $216,000. Hedge funds and other institutional investors own 49.03% of the company’s stock.
Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.06. Equities analysts predict that Kezar Life Sciences will post -1.95 earnings per share for the current year.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
See Also: Diversification
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.